VZV IgG and IgG avidity ELISA Kit

Name: VZV IgG and IgG avidity ELISA Kit
SKU: DEIA473
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, Plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The kit is intended for professional use for the qualitative and semiquantitative detection of IgG antibodies to varicella zoster virus (VZV) in human serum or plasma and to determine the avidity of IgG antibodies. The test is also useful in the diagnosis of VZV-associated diseases, namely varicella and herpes zoster. The test can also be utilized for the differential diagnosis of neuroinfections (encephalitis, meningitis, cerebellitis, vasculitis, myelitis and inflammatory neuropathies), infections of the eye and of exanthematous diseases of the skin. The kit is intended for differentiation of primary and recurrent VZV infection. Primary infection induces mainly low avidity (bind with low affinity) IgG antibodies to viral antigens. Later, antibodies with high avidity prevail. The predominance of low avidity IgG antibodies indicates recent primary infection. In other words, individuals with predominance of high avidity antibodies underwent the primary infection in the past. If such individuals have the symptoms of active VZV infection, it usually means the reactivation of the infection.

Contents of Kit

1. ELISA break-away strips in the handling frame coated with the specific antigen STRIPS Ag, 1 × 12 pcs
2. 1.3 mL of positive control human serum containing high avidity antibodies (High avidity control serum) r.t.u.¹⁾ HIGH AVID, 1 vial
3. 1.3 mL of positive control human serum containing low avidity antibodies (Low avidity control serum) r.t.u. LOW AVID, 1 vial
4. 1.3 mL Standard A = Negative control human serum, r.t.u. ST A/NC, 1 vial
5. 2.0 mL Standard D = Calibrator (human serum), r.t.u. ST D/CAL, 1 vial
6. 1.3 mL Standard E = Positive control human serum, r.t.u. ST E/PC, 1 vial
7. 13 mL Anti-human IgG animal antibodies labelled with horseradish peroxidase (anti-IgG Px conjugate) r.t.u. CONJ, 1 vial
8. 55 mL Wash buffer, 10× concentrated WASH 10×, 1 vial
9. 60 mL Dilution buffer, r.t.u. DIL, 1 vial
10. 13 mL Chromogenic substrate TMB, r.t.u. (TMB/H₂O₂), TMB 1 vial
11. 13 mL Urea solution, r.t.u. UREA, 1 vial
12. 13 mL Stop solution, r.t.u. (0.4 M sulfuric acid) STOP, 1 vial
13. Instruction manual
14. Quality Control Certificate
¹⁾ r.t.u., ready to use
Notice: Control sera may be colorless to yellowish or blue due to the use of different diluents.

Storage

2°C - 10°C

Performance Characteristics

Validity of the test
The absorbance value of the Dilution buffer DIL (BLANK = reaction background) is stated in the Quality Control Certificate of the lot.
The OD values of the standards / control sera and the ratio of the OD values of the standards ST E/PC / ST D/CAL should be within the ranges stated in the Quality Control Certificate of the lot.
The Calibrator and Controls are human sera, and as such they may show inhomogeneity, if their value in the test is significantly different from the values stated in the Certificate of analysis, consult the results with the manufacturer.

Precision

The interassay variability (between tests) and the intraassay variability (within the test) were determined by testing samples with different OD values.
1. Repeatability (intraassay)
The variation coefficient of intraassay is max. 8 %. It is measured for each particular lot at least on 12 parallels of the same microtiter plate.

2. Reproducibility (interassay)
The variation coefficient of reproducibility is a maximum of 15 %. It is measured for each lot by comparing the wells of the same sample in several consecutive tests.

Detection Range

The measuring range is determined by the measuring capability of the spectrophotometer / colorimeter used.

Sensitivity

Sensitivity and specificity of the test
The evaluation of the diagnostic sensitivity and the specificity of the test was performed by the comparing the kit with two other commercial ELISA tests and with indirect immunofluorescence test.

* Equivocal results were not taken in account for calculation
a. Analytical sensitivity of the test
The analytical sensitivity of the assay is defined as the mean of the sample without analyte plus three times of the standard deviation and represents the lowest detectable antibody titer. The analytical sensitivity value is determined for each kit lot and is stated in the Quality Control Certificate of that kit lot.
b. Analytical specificity of the test
The quality of the native antigen VZV, which recognizes specific antibodies in patient samples, ensures the high specificity and sensitivity of this assay. However, to determine the diagnosis, the test results must always be interpreted in the context of clinical signs and the results of other laboratory tests, see Interpretation Of Results.

Citations

Have you cited DEIA473 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Reagents for VZV Assay Development and Vaccine Research

QA & Reviews

Customer Reviews

References

Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report

BMC INFECTIOUS DISEASES

Authors: Furuto, Yoshitaka; Kawamura, Mariko; Namikawa, Akio; Takahashi, Hiroko; Shibuya, Yuko

Abstract

Background: Visceral disseminated varicella zoster virus (VDVZV) infection is a rare disease with a high mortality rate (55%) in immunocompromised patients, but it is not yet widely recognized in the field of nephrology. We report a case of VDVZV contracted during immunosuppressive therapy for membranous nephropathy. Case presentation: A 36-year-old woman was diagnosed with membranous nephropathy and was being treated with immunosuppressive therapy consisting of 60 mg/day prednisolone, 150 mg/day mizoribine, and 150 mg/day cyclosporine. Nephrosis eased; therefore, the prednisolone dosage was reduced. However, 50 days after starting immunosuppressive therapy, the patient suddenly developed strong and spontaneous abdominal pain, predominantly in the epigastric area, without muscular guarding or rebound tenderness. Blood data indicated neutrophil-dominant elevated white blood cell count, reduced platelet count, elevated transaminase and lactate dehydrogenase, slightly increased C-reactive protein, and enhanced coagulability. Abdominal computed tomography revealed a mildly increased enhancement around the root of the superior mesenteric artery with no perforation, intestinal obstruction, or thrombosis. The cause of the abdominal pain was unknown, so the patient was carefully monitored and antibiotic agents and opioid analgesics administered. The following day, blisters appeared on the patient's skin, which were diagnosed as varicella. There was a marked increase in the blood concentration of VZV-DNA; therefore, the cause of the abdominal pain was diagnosed as VDVZV. Treatment with acyclovir and immunoglobulin was immediately started, and the immunosuppressive therapy dose reduced. The abdominal pain resolved rapidly, and the patient was discharged 1 week after symptom onset. Discussions and conclusions: This patient was VZV-IgG positive, but developed VDVZV due to reinfection. Abdominal pain due to VDVZV precedes the skin rash, which makes it difficult to diagnose before the appearance of the rash, but measuring the VZV-DNA concentration in the blood may be effective. Saving the patient's life requires urgent administration of sufficient doses of acyclovir and reduced immunosuppressive therapy.

Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women

JOURNAL OF INFECTIOUS DISEASES

Authors: Perciani, Catia T.; Sekhon, Manmeet; Hundal, Sabrina; Farah, Bashir; Ostrowski, Mario A.; Anzala, A. Omu; McKinnon, Lyle R.; Jaoko, Walter; MacDonald, Kelly S.

Abstract

Background. Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immuno-deficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZV(Oka) vaccination. Methods. Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results. Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P <.0001) and 1.6-fold rise in immunoglobulin A (IgA) (P =.004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions. VZV(Oka) vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity.